Evotec

#Bill & Melinda Gates Foundation #Biologics #Evotec #Funding #Infectious diseases #Monoclonal antibodies

Grant supports Evotec’s AI-driven optimisation of mAbs

Evotec subsidiary Just – Evotec Biologics has received a new grant from the Gates Foundation to enable global access to biotherapeutics utilising its molecular design suite of computational technologies, called J.MD.  The investment continues the support for selected Gates Foundation grantees to improve the developability and reduce… Read More

#Business & Investment #News

#Antisense Oligonucleotides (ASOs) #Collaboration #Evotec #Partnership #Rare disease #SynaptixBio

SynaptixBio and Evotec extend rare disease therapies partnership

SynaptixBio and Evotec have announced they are extending their partnership to find further candidate drugs to treat H-ABC, the most severe form of TUBB4A leukodystrophy. The drug research was originally carried out by the Children’s Hospital of Philadelphia (CHOP), the world’s leading centre for leukodystrophy research,… Read More

#News

#Collaboration #Evotec #France #Infectious diseases #Pfizer

Evotec and Pfizer collaborate on metabolic and infectious diseases

Evotec and Pfizer have entered into a multi-year research collaboration, initially focused on early discovery research for metabolic and infectious diseases. The research will be carried out at Evotec’s sites in France, including Campus Curie in Toulouse with capabilities spanning high throughput screening, in vitro and… Read More

#Business & Investment #News

#Evotec #Genomics #High throughput screening #Metabolomics #Multi-omics #Proteomics #Transcriptomics

PanOmics: Advancing drug discovery

This article is sponsored by Evotec. To enable Evotec’s precision medicine approach, we have been building technology platforms that allow PanOmics or multi-omics data generation at an industrialised scale. The technologies cover the whole range of biomolecules from genes to protein to metabolites. While we are using… Read More

#News

#Bristol Myers Squibb #Collaboration #Evotec #Neurodegenerative disorders #Neuroscience

Evotec and BMS enter drug discovery licence agreement

Evotec and Bristol Myers Squibb (BMS) have entered into an exclusive global licence agreement, extending their neuroscience partnership. The agreement covers selected late-stage discovery programmes that were developed and progressed within the collaboration between the two companies. Evotec and BMS originally entered their neurodegeneration… Read More

#News

Monoclonal antibody
#Bayer #Evotec #Kidney disease #Monoclonal antibodies #Phase I trial

First patient dosed in trial of antibody for kidney disease

The first patient has been dosed in the clinical Phase I evaluation of the Sema3A monoclonal antibody, part of the Evotec-Bayer multi-target research collaboration in kidney diseases. The drug candidate, a monoclonal antibody (mAb) targeting the protein Semaphorin-3A (Sema3A), is being developed as a potential first-to-market… Read More

#News

PanHunter
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Case study #Evotec #Machine learning #Multi-omics #Omics #Software

Case study: The PanHunter multi-omics analysis platform

A new Case Study is available, sponsored by Evotec. The study of health and disease through multi-omics research generates vast amounts of interconnected data. Unlocking their secrets requires complex bioinformatic exploration. This analysis is accelerated by a dedicated and flexible software application that is not only reliable and provides… Read More

#News

RNA strand
#Evotec #Funding #Immunology / Virology & Vaccines #Pandemic prevention #RNA #RNA sequencing

Grant supports discovery of RNA-targeting Henipavirus therapeutics

Evotec has received a $1.7 million grant from Open Philanthropy, a philanthropic funder prioritising global health and wellbeing. Under the grant, Evotec aims to discover and develop RNA-targeting small molecules as potential first-in-class therapeutics against Henipaviruses. Henipavirus is a genus of zoonotic viruses that… Read More

#News